Abel Hall LLC
LXEO icon

Abel Hall LLC’s Lexeo Therapeutics LXEO Stock Holding History

Abel Hall LLC’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$42.7K Buy
+12,642
New +$57.2K 0.01% 841

Other funds holding LXEO

Hennion & Walsh Asset Management
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return
Y-Intercept (HK)
Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return
Nisa Investment Advisors
Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
Essential Partners
Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return
Fortitude Family Office
Fortitude Family Office Scottsdale, Arizona $586M AUM 20.58% 1-Year Est. Return
SBI Securities
SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return
True Wealth Design
True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return
IFP Advisors
IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return

Abel Hall LLC's LXEO Position: Q3 2026 in Review

Abel Hall LLC opened a new position in Lexeo Therapeutics (LXEO) in Q3 2026: 12,642 shares worth $42.7K. The stake represents 0.01% of the portfolio and ranks #841 among its holdings.

12 funds tracked by Wall St. Rank hold LXEO as of Q3 2026.

  • Abel Hall LLC held 12,642 shares of Lexeo Therapeutics worth $42.7K as of Q3 2026.
  • Lexeo Therapeutics was a new Abel Hall LLC position in Q3 2026.
  • Lexeo Therapeutics made up 0.01% of Abel Hall LLC's portfolio in Q3 2026, its #841 holding.
  • 12 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q3 2026.

Based on Abel Hall LLC's 13F filing for Q3 2026, filed 19 Oct 2026.